|
|
|
|
|
|
|
|
|
20.08.25 - 14:18
|
Eli Lilly Ranks Among Top Large-Cap Performers as GLP-1 Drug Sales Exceed Billions (24/7 Wall St.)
|
|
|
Eli Lilly (NYSE:LLY) has quickly emerged as one of Wall Street's biggest winners, fueled by explosive demand for its new generation of weight-loss and diabetes treatments. The company's GLP-1 drugs, including Mounjaro and the newly approved Zepbound, have turned into blockbuster products, generating billions in sales and reshaping the pharmaceutical landscape. As a result, Eli […]
The post Eli Lilly Ranks Among Top Large-Cap Performers as GLP-1 Drug Sales Exceed Billions appeared first on 24/7 Wall St.....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
19.08.25 - 07:30
|
Eli Lilly-Aktie: Insider schlägt zu – klare Kaufchance? (Sharedeals)
|
|
|
Die Aktie von Eli Lilly konnte sich zuletzt deutlich erholen. Nun wurde auch noch ein signifikanter Insider-Kauf bekannt. Spricht jetzt alles für einen Einstieg bei dem gefallenen Engel? CEO greift zu Zuletzt ist die Aktie von Eli Lilly genauso wie die des Konkurrenten Novo Nordisk massiv an der Börse unter Druck geraten. Doch diese Gelegenheit […]
The post Eli Lilly-Aktie: Insider schlägt zu – klare Kaufchance? first appeared on sharedeals.de....
|
|
|
|
|
|
|
|
|
18.08.25 - 13:48
|
Novo Shares Gain As Wegovy Wins FDA Approval For Liver Disease (ZeroHedge)
|
|
|
Novo Shares Gain As Wegovy Wins FDA Approval For Liver Disease
Novo Nordisk shares gained in Copenhagen trading on Monday after the U.S. FDA approved Wegovy for the treatment of metabolic-associated steatohepatitis (MASH), a severe form of liver disease. The approval gives Novo a first-mover advantage over Eli Lilly in the U.S. market.
Year-to-date, Novo shares have lost nearly 50% amid intensifying GLP-1 competition, including Eli Lilly's obesity drug Zepbound and copycat threats (GLP-1 compounds) from companies such as telehealth company Hims & Hers Health. The MASH approval offers a potential incremental growth driver and could reverse some of the negative sentiment surrounding the stock this year. This raises the question for investors whether current stock levels represent a buy-the-dip opportunity.
The FDA's decision marks the second positive news for Novo this month, following Lilly's oral obesity pill, orforglipron, that met its primary endpoints but fell short of Wal...
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
